학술논문

Comprehensive molecular profiling of lung adenocarcinoma
Document Type
article
Author
Collisson, Eric ACampbell, Joshua DBrooks, Angela NBerger, Alice HLee, WilliamChmielecki, JuliannBeer, David GCope, LeslieCreighton, Chad JDanilova, LudmilaDing, LiGetz, GadHammerman, Peter SNeil Hayes, DHernandez, BryanHerman, James GHeymach, John VJurisica, IgorKucherlapati, RajuKwiatkowski, DavidLadanyi, MarcRobertson, GordonSchultz, NikolausShen, RonglaiSinha, RileenSougnez, CarrieTsao, Ming-SoundTravis, William DWeinstein, John NWigle, Dennis AWilkerson, Matthew DChu, AndyCherniack, Andrew DHadjipanayis, AngelaRosenberg, MaraWeisenberger, Daniel JLaird, Peter WRadenbaugh, AmieMa, SingerStuart, Joshua MAverett Byers, LaurenBaylin, Stephen BGovindan, RamaswamyMeyerson, MatthewGabriel, Stacey BCibulskis, KristianKim, JaegilStewart, ChipLichtenstein, LeeLander, Eric SLawrence, Michael SKandoth, CyriacFulton, RobertFulton, Lucinda LMcLellan, Michael DWilson, Richard KYe, KaiFronick, Catrina CMaher, Christopher AMiller, Christopher AWendl, Michael CCabanski, ChristopherMardis, ElaineWheeler, DavidBalasundaram, MirunaButterfield, Yaron SNCarlsen, RebeccaChuah, EricDhalla, NoreenGuin, RanabirHirst, CarrieLee, DarleneLi, Haiyan IMayo, MichaelMoore, Richard AMungall, Andrew JSchein, Jacqueline ESipahimalani, PayalTam, AngelaVarhol, RichardGordon Robertson, AWye, NatasjaThiessen, NinaHolt, Robert AJones, Steven JMMarra, Marco AImielinski, MarcinOnofrio, Robert CHodis, EranZack, Travis
Source
Nature. 511(7511)
Subject
Rare Diseases
Genetics
Biotechnology
Clinical Research
Lung Cancer
Human Genome
Cancer
Lung
Aetiology
2.1 Biological and endogenous factors
Adenocarcinoma
Adenocarcinoma of Lung
Cell Cycle Proteins
Female
Gene Dosage
Gene Expression Regulation
Neoplastic
Genomics
Humans
Lung Neoplasms
Male
Molecular Typing
Mutation
Oncogenes
Sex Factors
Transcriptome
Cancer Genome Atlas Research Network
General Science & Technology
Language
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis.